Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Annals of Clinical and Translational Neurology · 2026
DOI: 10.1002/acn3.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Lea Gerischer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology With Experimental Neurology and Integrated Myasthenia Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie U…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Myasthenia Gravis, Complement Pathway, Alternative, Complement Inactivating Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Methods
In this prospective, exploratory real‐world study CH50 and AH50, eculizumab and ravulizumab blood levels were assessed in patients with acetylcholine‐receptor‐antibody (AChR‐ab) positive gMG. Patients were either pretreated with eculizumab or C5‐inhibitor naïve. Samples were collected before the next infusion (end‐of‐dose). Laboratory data were correlated with patient‐reported subjective duration of the ravulizumab effect.
Results
Overall, 61 patients were enrolled. At the end of their respective dosing interval, median AH50 levels were more strongly suppressed with eculizumab than with ravulizumab (1% [0%–2%] versus 5% [3%–9%]; Cohen's d 2.2 [95% CI 1.5–2.8]). Patients who discontinued ravulizumab due to insufficient effects ( n = 19; 33%) had higher median AH50 levels than those who continued (7% [4%–13%] versus 5% [3%–8%]; Cohen's d −0.9 [95% CI −1.3 to −0.4]). In 81% ( n = 46) of patients, the therapeutic effect of ravulizumab diminished before the subsequent infusion after the standard 8‐week interval. Higher AH50 levels were correlated with earlier symptom recurrence.
Interpretation
Our results indicate potential differences in the ability of eculizumab and ravulizumab to suppress complement pathway activity through their respective dosing intervals. Additionally, higher AH50 levels might be a potential biomarker to predict poor therapy response and faster wearing off of ravulizumab's effect. However, these findings need to be validated in large multicenter studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology With Experimental Neurology and Integrated Myasthenia Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
- Laboratory of Complement Diagnostics, Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder-Braunstein, Guido Wabnitz, Jan D Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel
Zitieren
APA
Gerischer, L., Stascheit, F., Mönch, M., Doksani, P., Dusemund, C., Herdick, M., Mergenthaler, P., Stein, M., Suboh, A., Schröder-Braunstein, J., Wabnitz, G., Lünemann, J. D., Lehnerer, S., Hoffmann, S., & Meisel, A. (2026). Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70251
Vancouver
Gerischer L, Stascheit F, Mönch M, Doksani P, Dusemund C, Herdick M, et al. Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70251
BibTeX
@article{Gerischer2026,
author = {Gerischer, Lea and Stascheit, Frauke and Mönch, Maximilian and Doksani, Paolo and Dusemund, Carla and Herdick, Meret and Mergenthaler, Philipp and Stein, Maike and Suboh, Amani and Schröder-Braunstein, Jutta and Wabnitz, Guido and Lünemann, Jan D and Lehnerer, Sophie and Hoffmann, Sarah and Meisel, Andreas},
title = {Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70251}
}
EUVIMED